The new drug for severe asthma, ‘Tezpire' is soon to enter the Korean market.

According to industry sources, AstraZeneca Korea has submitted an application for the approval of ‘Tezspire (tezepelumab)’ in Q2 to the Ministry of Food and Drug Safety and is receiving review. At this pace, Tezspire is expected to be commercialized in the second half of the year.

As a viable competitor to Sanofi’s ‘Dupixent (dupilumab),’ Tezspire inhibits the action of the thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades, to block the inflammatory chain reaction.

The drug was approved by the US FDA in 2021 as a treatment